Canaccord Genuity Initiates Coverage On Taysha Gene Therapies with Buy Rating, Announces Price Target of $16
Canaccord Genuity analyst Whitney Ijem initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and announces Price Target of $16.